Evidence map›Paper›PMID 31273416›Full record

Trial reportIntensive care medicine2019

Continual hemodynamic monitoring with a single-use transesophageal echocardiography probe in critically ill patients with shock: a randomized controlled clinical trial.

Tobias M Merz, Luca Cioccari, Pascal M Frey, Andreas Bloch, David Berger, Bjoern Zante, Stephan M Jakob, Jukka Takala

Erratum issued Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Intensive care medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02048566 (ImaCor II Effects of Hemodynamic Monitoring Using the ImaCor Single Use Transesophageal Echocardiography Probe in Critically Ill Patients - a Randomized Controlled Trial), which is not on this map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02048566 nacompletednot on this map

ImaCor II Effects of Hemodynamic Monitoring Using the ImaCor Single Use Transesophageal Echocardiography Probe in Critically Ill Patients - a Randomized Controlled Trial

TypeinterventionalSponsorInsel Gruppe AG, University Hospital BernRan2014 to 2018Enrolled550ConditionsShockArmsImaCor PM, ImaCor SM, Control PM, Control SM
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Focus on ultrasound in intensive care.Intensive care medicine · 2020
    Article
  17. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Tobias M MerzDepartment of Intensive Care Medicine, University Hospital, University of Bern, 3010, Bern, Switzerland. TobiasM@adhb.govt.nz.ORCID http://orcid.org/0000-0002-3149-5873
Luca CioccariDepartment of Intensive Care Medicine, University Hospital, University of Bern, 3010, Bern, Switzerland.
Pascal M FreyDepartment of General Internal Medicine, University Hospital, University of Bern, Bern, Switzerland.
Andreas BlochDepartment of Intensive Care Medicine, University Hospital, University of Bern, 3010, Bern, Switzerland.
David BergerDepartment of Intensive Care Medicine, University Hospital, University of Bern, 3010, Bern, Switzerland.
Bjoern ZanteDepartment of Intensive Care Medicine, University Hospital, University of Bern, 3010, Bern, Switzerland.
Stephan M JakobDepartment of Intensive Care Medicine, University Hospital, University of Bern, 3010, Bern, Switzerland.
Jukka TakalaDepartment of Intensive Care Medicine, University Hospital, University of Bern, 3010, Bern, Switzerland.
University of Bern · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMortality in circulatory shock is high. Enhanced resolution of shock may improve outcomes. We aim to determine whether adding hemodynamic monitoring with continual transesophageal echocardiography (hTEE) to usual care accelerates resolution of hemodynamic instability.

methods550 patients with circulatory shock were randomly assigned to four groups stratified using hTEE (hTEE vs usual care) and assessment frequency (minimum every 4 h vs 8 h). Primary outcome was time to resolution of hemodynamic instability, analyzed as intention-to-treat (ITT) analysis at day 6 and in a predefined secondary analysis at days 3 and 28.

resultsOf 550 randomized patients, 271 with hTEE and 274 patients with usual care were eligible and included in the ITT analysis. Time to resolution of hemodynamic instability did not differ within the first 6 days [hTEE vs usual care adjusted sub-hazard ratio (SHR) 1.20, 95% confidence interval (CI) 0.98-1.46, p = 0.067]. Time to resolution of hemodynamic instability during the 72 h of hTEE monitoring was shorter in patients with TEE (hTEE vs usual care SHR 1.26, 95% CI 1.02-1.55, p = 0.034). Assessment frequency had no influence. Time to resolution of clinical signs of hypoperfusion, duration of organ support, length of stay and mortality in the intensive care unit and hospital, and mortality at 28 days did not differ between groups.

conclusionsIn critically ill patients with shock, hTEE monitoring or hemodynamic assessment frequency did not influence resolution of hemodynamic instability or mortality within the first 6 days. TRIAL REGISTRATION AND STATISTICAL ANALYSIS PLAN: ClinicalTrials.gov Identifier: NCT02048566.

Indexed as

AgedCritical IllnessEchocardiography, TransesophagealFemaleHemodynamic MonitoringHumansIntensive Care UnitsLogistic ModelsMaleMiddle AgedProportional Hazards ModelsShockSwitzerlandCirculatory shockHemodynamic monitoringHemodynamic transesophageal echocardiography (hTEE)Randomized controlled trial

Identifiers

PMID31273416
OpenAlexW2955068519

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.